1 A Machine Learning Model Incorporating Laboratory Blood Tests Discriminates Between SARS-CoV-2

2 and Influenza Infections at Emergency Department Visit

- Junyi Liu¹, Lars F. Westblade^{2,3,4}, Amy Chadburn^{2,3}, Richard Fideli^{2,3}, Arryn Craney^{2,3}, Sophie Rand²,
- 4 Melissa Cushing^{2,3}, Zhen Zhao^{2,3}, Jingjing Meng^{1*}, He S. Yang^{2,3*}
- 5
- ¹Department of Computer Science and Engineering, University of Buffalo, Buffalo, NY, USA
- 7 ²Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
- 8 ³New York-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA
- ⁴Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA
- 10
- 11
- 12 *Joint corresponding authors
- 13 <u>Correspondence to:</u>
- 14 He S. Yang, PhD
- 15 Department of Pathology and Laboratory Medicine
- 16 Weill Cornell Medicine
- 17 525 E. 68th Street, Suite F 707, New York, NY 10065
- 18 Email: hey9012@med.cornell.edu
- 19 Phone: 212-746-6292

- 20 Jingjing Meng, PhD
- 21 Department of Computer Science and Engineering
- 22 University of Buffalo
- 23 304 Davis Hall, Buffalo. NY
- 24 Email: Jmeng2@buffalo.edu
- 25 Phone: 716-645-0566
- 26

27

28	Key words: SARS-CoV-2, COVID-19, influenza, machine learning, random forest, routine laboratory tests
29	Abbreviation: AGAP: anion gap, COVID-19: corona virus disease-2019; SARS-CoV-2: severe acute
30	respiratory syndrome coronavirus 2; TAT: turn-around time; ED: emergency department; RT-PCR: real-
31	time reverse transcription polymerase chain reaction; WBC: white blood cells; RBC: red blood cells;
32	RDW-CV: Red blood cell distribution width; BUN: Blood urea nitrogen; MCV: Mean corpuscular volume;
33	AUC: Area under the receiver operating characteristic curve; NYPH/WCM: New York Presbyterian
34	Hospital/Weill Cornell Medicine; NYPH/LMH: New York Presbyterian Hospital/Lower Manhattan
35	Hospital.
36	Running title: Model discriminates COVID-19 and influenza
37	Word count: 2417
38	

41 Abstract

42	Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus are
43	contagious respiratory pathogens with similar symptoms but require different treatment and
44	management strategies. This study investigated whether laboratory blood tests can discriminate
45	between SARS-CoV-2 and influenza infections at emergency department (ED) presentation.
46	Methods: 723 influenza A/B positive (2018/1/1 to 2020/3/15) and 1,281 SARS-CoV-2 positive
47	(2020/3/11 to 2020/6/30) ED patients were retrospectively analyzed. Laboratory test results completed
48	within 48 hours prior to reporting of virus RT-PCR results, as well as patient demographics were included
49	to train and validate a random forest (RF) model. The dataset was randomly divided into training ($2/3$)
50	and testing (1/3) sets with the same SARS-CoV-2/influenza ratio. The Shapley Additive Explanations
51	technique was employed to visualize the impact of each laboratory test on the differentiation.
52	Results: The RF model incorporating results from 15 laboratory tests and demographic characteristics
53	discriminated SARS-CoV-2 and influenza infections, with an area under the ROC curve value 0.90 in the
54	independent testing set. The overall agreement with the RT-PCR results was 83% (95% CI: 80-86%). The
55	test with the greatest impact on the differentiation was serum total calcium level. Further, the model
56	achieved an AUC of 0.82 in a new dataset including 519 SARS-CoV-2 ED patients (2020/12/1 to
57	2021/2/28) and the previous 723 influenza positive patients. Serum calcium level remained the most
58	impactful feature on the differentiation.
59	Conclusion: We identified characteristic laboratory test profiles differentiating SARS-CoV-2 and
60	influenza infections, which may be useful for the preparedness of overlapping COVID-19 resurgence and
61	future seasonal influenza.

62

64 Introduction:

65 Both the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiology agent of 66 coronavirus disease 2019 (COVID-19), and influenza virus are contagious respiratory pathogens, which cause as a wide range of illnesses from asymptomatic or mild through to severe disease and death.¹ 67 However, the fraction of severe infection cases, as well as the mortality rate, is higher in COVID-19 than 68 in influenza.² Transmissibility, estimated by the basic reproductive rate (R_0), is also higher in SARS-CoV-2. 69 $(R_0 \sim 2.5)$ compared to influenza $(R_0 \sim 1.7)$.³ The SARS-CoV-2 and influenza virus infections have similar 70 71 symptoms, such as cough, sore throat, fever, fatigue, and myalgias, making clinical differentiation at 72 hospital presentation challenging without the aid of laboratory tests. Currently, the detection of these 73 pathogens relies on viral specific real-time reverse-transcription polymerase chain reaction (RT-PCR) testing of nasopharyngeal swabs or other upper respiratory track specimens.⁴ However, while the turn-74 75 around time (TAT) of RT-PCR testing is usually within a day, it can be substantially longer due to reagent 76 shortages⁵ as experienced during the COVID-19 pandemic, or lack of on-site testing, particularly in many 77 of the smaller and more rural hospitals. Since the treatment of SARS-CoV-2 and influenza is different, delayed identification of infected patients may result in inappropriate patient management and 78 79 increased risk of infection for healthcare personnel. Therefore, rapid discrimination of SARS-CoV-2 and 80 influenza infections, and identification of high-risk patients is vital for individual patient care and for 81 controlling disease transmission.

Routine laboratory tests provide objective and quantifiable characterization of the effects of the virus on
the human body⁶. Routine test results are generally available within 1-2 hours and are accessible prior to
patient discharge from the emergency department (ED). Previous studies^{7, 8}, including our own
publications⁹, have demonstrated that machine learning models incorporating routine laboratory blood
tests and demographics can differentiate and predict SARS-CoV-2 infected and non-infected patients.
Machine learning algorithms have the capability of revealing complicated pattern or trend behind high-

88	dimensional laboratory data that are challenging for human eyes to visualize. So far, limited studies have
89	investigated the differences in laboratory blood test results between SARS-CoV-2 and influenza
90	infections ^{3, 10} . While no single laboratory test strongly associates with SARS-CoV-2 or influenza infection,
91	we investigated whether a combination of multiple routine laboratory tests can discriminate between
92	these two viral infections at an early stage of disease, and aimed to find out the most impactful
93	laboratory features that contribute to the discrimination. Furthermore, COVID-19 has been evolving
94	since the initial outbreak of the disease ¹¹ . We are interested in understanding whether the impactful
95	laboratory features remain unchanged in more recent COVID-19 positive patients during the 2020-2021
96	winter wave.

97

99 Methods

100 Patient cohorts

101 We reviewed retrospectively laboratory and demographic data of 723 influenza A/B positive patients 102 from January 1, 2018 to March 15, 2020, and 1,281 SARS-CoV-2 positive patients from March 11, 2020 103 to June 30, 2020, evaluated in the ED of a New York City academic hospital. Routine influenza RT-PCR 104 testing was suspended from March to September 2020 to prioritize resources for SARS-CoV-2 testing. 105 The SARS-CoV-2 cohort included infected patients from the initial outbreak as well as from the post-106 apex phase. Influenza or SARS-CoV-2 RT-PCR results, routine laboratory testing results within 2 days 107 prior to the completion of RT-PCR testing, and patient demographic information were obtained from the 108 laboratory information system (Cerner Millennium, Cerner Corporation). Exclusion criteria included 109 patients < 18 years of age, and patients who lacked laboratory test results within the designated time 110 window (within 2 days prior to RT-PCR results release). In total, the final dataset included results from 111 1,237 SARS-CoV-2 RT-PCR positive patients and 513 influenza positive (393 type A, and 119 type B, 1 112 A/B) ED patients (Figure 1). This study was approved by the Institutional Review Board (IRB) of Weill 113 Cornell Medicine and deemed IRB exempt by the University of Buffalo. 114 From December 1, 2020 to February 28, 2021, there were a total of 559 SARS-CoV-2 RT-PCR positive 115 patients and only 1 influenza RT-PCR positive patient (this patient was also positive for SARS-CoV-2) who 116 were evaluated in the ED of our hospital. After applying the exclusion criteria as state above, 519 SARS-117 CoV-2 positive patients were included in the new dataset. Since there were only 1 positive influenza 118 case during the same time, we had to compare the new SARS-CoV-2 dataset to the previous influenza 119 dataset from 2018/1/1 to 2020/3/11.

120

122 Model construction

123	A total of 57 chemistry, hematology, and coagulation tests commonly ordered in these patients were
124	examined in the SARS-CoV-2 and influenza cohorts. Of them, 15 laboratory tests were selected to be
125	included in the model based on two criteria: 1) a result available for at least 70% of the patients within
126	48 hours before a specific SARS-CoV-2 RT-PCR test and 2) showing a significant difference (P-value after
127	Bonferroni correction less than 0.05) between influenza and SARS-CoV-2 positive patients. After the
128	feature selection, a 22-dimensional vector (15 laboratory tests, one age, one gender, five race variables
129	(African American, Asian, Caucasian, others and unknown) was constructed to represent every SARS-
130	CoV-2 or influenza RT-PCR test result (Figure 2). If one laboratory test was ordered multiple times within
131	48 hours, an average of the values was calculated and used for analysis. The missing value of a specific
132	laboratory test in a feature vector was imputed by the mean value of the available non-missing values of
133	that dimension over all patients. Subsequently, a random forest classifier model was developed
134	incorporating the results of 15 selected laboratory tests and patient age, gender, and race, using the
135	Python scikit-learn package 0.23.2. The whole data set was randomly split into a training set (2/3 of
136	cases) and a testing set (1/3 cases) with the same ratio of SARS-CoV-2/influenza cases as the ratio for
137	the overall cases. The hyperparameters of random forest model was trained using 5-fold cross
138	validation, where all RT-PCR tests in the training set were randomly partitioned into 5 equal buckets
139	with the same SARS-CoV-2/influenza ratio. The random forest model was then trained using selected
140	hyperparameters with all RT-PCR tests in the training set. The performance of the model was evaluated
141	in the independent testing set using area under the receiver operating characteristic curve (ROC),
142	sensitivity, specificity, and agreement with RT-PCR. The Shapley Additive Explanations (SHAP) technique
143	was employed to visualize the impact of each laboratory test on the differentiation.

144

145

146 Results:

147	Patients with SARS-CoV-2 infection were significantly older (median: 64 years, IQR: 51-75) than those
148	with influenza (median: 48 years, IQR: 32-63, $p < 0.001$). The percentage of male patients was also
149	significantly higher in SARS-CoV-2 cohort (58.36%) than in the influenza group (41.33%, p < 0.001). In
150	addition, a significantly lower percentage of African American was present in the SARS-CoV-2 group than
151	the influenza cohort (p = 0.02, Table 1).
152	The laboratory results completed within 48 hours prior to a positive SARS-CoV-2 or influenza RT-PCR

test result were included in the analysis. A total of 15 laboratory test results with missing rate < 30%

154 were found to be significantly different between the SARS-CoV-2 and influenza infected patients at their

155 ED presentation. The performance of the random forest model incorporating these 15 laboratory tests

and patient age, sex and race achieved an area under the ROC curve (AUC) value of 0.90 (95% CI: 0.88-

157 0.93) in the independent testing set. The overall agreement with the RT-PCR, determined at the

158 Youden's index point, was 83% (95% CI: 80-86%), with 87% (95% CI: 84-90%) agreement with SARS-CoV-

159 2 RT-PCR results and 73% (95% CI: 66-80%) agreement with the influenza RT-PCR results. The random

160 forest model generated a probability score, from 0 to 1, to differentiate influenza vs. SARS-CoV-2

161 infection (cutoff 0.58 at the Youden' index point).

162 In order to visualize and interpret the impact of each laboratory test to the overall differentiation, a 163 Shapley Additive Explanations (SHAP) technique (Version 4.10.0) was employed which assigns each 164 feature a value of importance (the SHAP value) for the differentiation of SARS-CoV-2 or influenza 165 infections. A summary plot is shown in **Figure 2**, in which the impact of each laboratory test and 166 demographic feature was ordered from high to low. Notably, serum calcium level had the greatest 167 impact on the differentiation of these two infections. The SARS-CoV-2 patients demonstrated 168 significantly lower serum calcium concentrations than the influenza positive patients. In addition, the 169 peripheral monocyte and basophil counts were significantly lower whereas the lymphocyte and white

170 blood cell counts were significantly higher in the SARS-CoV-2 patients compared to the influenza

- 171 patients. The SARS-CoV-2 patients also demonstrated hypochloremia, hyperglycemia, higher
- 172 BUN/creatinine ratio and higher anion gap compared to the influenza patients.

173 Since the COVID-19 has been evolving since the initial outbreak, we further investigated whether our 174 random forest model is still discriminative between SARS-COV-2 and influenza in the 2020-2021 winter 175 wave and whether the top laboratory tests are still impactful on the differentiation. From December 1, 176 2020 to February 28, 2021, there were a total of 559 SARS-CoV-2 RT-PCR positive patients evaluated in 177 the ED of our hospital, and among them, 519 were included in our dataset after the exclusion criteria 178 was applied (Demographic information in Table 1). However, there was only one positive influenza case 179 identified in the ED during this time period, and this patient was also positive for SARS-CoV-2 RT-PCR 180 testing. Therefore, we test our model on the new SARS-CoV-2 dataset with the previous 723 influenza 181 A/B positive patients from January 1, 2018 to March 15, 2020. The random forest model with the same 182 parameters achieved an AUC of 0.82 with an overall agreement of 74% (95% CI: 71-77%) using the same 183 cutoff value. Agreement with SARS-CoV-2 and influenza RT-PCR results was 75% and 73%, respectively. 184 Interestingly, serum calcium level remains the most impactful laboratory feature on the differentiation 185 of SARS-CoV-2 and influenza infections (Figure 3). Compared to the influenza positive patients, the more 186 recent SARS-CoV-2 positive patients still exhibited hypocalcemia, lower level of monocyte counts, and 187 higher levels of lymphocyte, WBC, and neutrophil counts as well as higher anion gap and BUN/creatinine 188 ratio.

189

191 **Discussion**:

192	This retrospective analysis illustrates that a combination of 15 laboratory tests, along with patient
193	demographics, can help distinguish between SARS-CoV-2 and influenza infections at an early stage of
194	disease. While SARS-CoV-2 and influenza infections show similar symptoms ² , each has a characteristic
195	laboratory test result profile that could be used for early disease differentiation and prediction.
196	Although the level of seasonal influenza was extremely low in the U.S. and other countries in the
197	northern hemisphere during the past winter ^{12, 13} , our findings pave the way for future research about
198	the distinct pathophysiological mechanisms underlying SARS-CoV-2 and other respiratory virus
199	infections, and may be useful for the preparedness of overlapping COVID-19 resurgence and future
200	seasonal influenza. Understanding the characteristic laboratory profiles associated with the two
201	pathogens may assist early and rapid identification of high-risk patients and optimize resource use
202	during periods of high infection rates for both SARS-CoV-2 and influenza, especially in areas where
203	hospitals or clinics do not have onsite RT-PCR testing for respiratory viruses.
204	Machine learning models can perform analysis of massive quantities of data and extract hidden patterns
205	that that would be challenging for human eyes to identify. A machine learning classification model
206	should make clinical and biologic sense. Here we report that in our machine learning classification
207	model, the serum total calcium level, among all routine laboratory tests, has the highest impact on the
208	differentiation of SARS-CoV-2 from influenza infections. Hypocalcemia has been previously reported as a
209	prevalent biochemical abnormality in SARS-CoV-2 infected patients with a marked negative influence on
210	disease severity, biochemical inflammation and thrombotic markers ¹⁴ , and has been proposed as an
211	independent risk factor for hospitalization due to COVID-19 ¹⁵ . While the exact underlying biologic
212	mechanism for hypocalcemia in SARS-CoV-2 infection is still unclear, it may be closely associated with
213	viral-associated multi-organ damage and increase in inflammatory cytokines ¹⁶ . Studies better
214	delineating the mechanism and impact of viral infections on calcium metabolism may suggest

therapeutic modalities in the future. In addition, SARS-CoV-2 patients exhibited lower monocyte and
basophil counts, higher white blood cell, neutrophil and lymphocyte counts, as well as hypochloremia,
hyperglycemia, higher BUN/creatinine ratio and higher anion gap, compared to influenza positive
patients. The substantial differences in laboratory result profile between SARS-CoV-2 and influenza
patients shed new lights on the reactions of human body to the two types of viral infections, which may
contribute to the different disease manifestations and outcomes.

221 The COVID-19 winter wave in New York was not as severe as the devastating first wave that hit the city 222 in March and April 2020. The number of hospitalized patients as well as the mortality rates were lower than those of the first wave¹⁷. More patients showed mild or asymptomatic disease, which may partly 223 224 explain why it was more difficult to differentiate SARS-CoV-2 and influenza infections from laboratory 225 test results and why the performance of our model with the same parameters has dropped in the new 226 dataset. The performance of the model can be improved with a continuous learning process that 227 involves model updating and parameter optimizing using the new data. Interestingly, despite the 228 evolvement of COVID-19, the laboratory features that have greatest impact on the differentiation 229 between the two viral infections have been stable in the longitudinal datasets. 230 A study limitation is that our model's performance has not been validated in a dataset including 231 concurrent SARS-CoV-2 and influenza positive patients as Influenza RT-PCR testing was suspended from 232 March to September 2020 to prioritize resources for SARS-CoV-2 testing. We attempted to collect new 233 data from November 2020 to February 2021, however, there was only one influenza positive case during 234 this time in our hospital ED. This observation was consistent with the extremely low level of seasonal

influenza in North America¹². Despite a lack of direct comparison, the characteristic profile of SARS-CoV-

236 2 in comparison to influenza infection is still valid and has the potential to impact patient care. The

237 performance of our model could be further improved when it is trained with more concurrent influenza

and SARS-CoV-2 patient data.

239 Conclusion:

240 The	proposed	random	forest model	incorporating ag	e, gender	, race and 15	routine laborato	ry tests can
---------	----------	--------	--------------	------------------	-----------	---------------	------------------	--------------

- 241 discriminate between SARS-CoV-2 and influenza infection during an initial patient ED visit. We identified
- 242 15 routine laboratory blood tests, which assist in separating of SARS-CoV-2 from influenza infection,
- 243 with serum calcium level being the most impactful feature. These characteristic laboratory test result
- 244 profiles associated with SARS-CoV-2 and influenza infections mirror the biologic effects of these viruses
- on patients and provides clinically an opportunity for early identification of high-risk patients. Our
- analysis demonstrates the utility of machine learning as an emerging technique to support the diagnosis
- of infectious diseases.
- 248
- 249
- 250

252 Author contribution:

- 253 JL for performing data analysis and manuscript editing; LFW for providing influenza data and manuscript
- editing; AC for manuscript editing; RF for organizing laboratory test results for COVID-19 and influenza
- 255 patients; AC for manuscript editing; SR for providing COVID-19 data; MC and ZZ for manuscript editing;
- 256 JM for supervision of data analysis and manuscript editing; HSY for conceptualization, project
- 257 supervision, data analysis, and writing and editing of the manuscript.

258

- 259 Conflict of Interest Disclosure:
- 260 None of the authors have conflict of interest in this project.
- 261 Funding:
- 262 There is no funding source for this study.

- 264
- 265

266	Table 1. Demogra	hic of SARS-CoV-2	and influenza	patient cohorts
	0			-

Demographics:	SARS-CoV-2 positive patients from 2020/3/11 to 2020/6/30 (n = 1,237)	Influenza positive patients from 2018/1/1 to 2020/3/15 (n = 513)	SARS-CoV-2 positive patients from 2020/12/1 to 2021/2/28 (n =519)
Age, years; medium (IQR)	64 (51-75)	48 (32-63) ^{*#}	61 (45-73)
Gender, male, n (%)	722 (58.36%)	212 (41.33%) ^{*#}	253 (48.75%)
Race:			
Asian	52 (4.20%)	32 (6.24%)	33 (6.36%)
African American	117 (9.46%)	66 (12.87%) [*]	71 (13.68%)
White	324 (26.19%)	153 (29.82%) [#]	21 (40.66%)
Other	213 (17.22%)	128 (24.95%) ^{*#}	93 (17.92%)
Unknown	531 (42.93%)	134 (26.12%) ^{*#}	111 (21.39%)

267 *p value < 0.05 between SARS-CoV-2 positive patients from 2020/3/11 to 2020/6/60 and influenza

268 positive patients from 2018/1/1 to 2020/3/15.

[#]p value < 0.05 between SARS-CoV-2 positive patients from 2020/12/1 to 2021/2/28 and influenza

270 positive patients from 2018/1/1 to 2020/3/15.

271

273 Figure 1



275 Figure 2



276

277

279 Figure 3.



281 Figure legends:

- Figure 1: Inclusion/exclusion cascade of SARS-CoV-2 and influenza patient cohorts in the dataset.
- Figure 2: Impact of each laboratory test and demographic feature to the overall differentiation of SARS-
- 284 CoV-2 and influenza infections in the random forest model. Dataset includes SARS-CoV-2 positive
- patients from 2020/3/15 to 2020/6/30, and influenza positive patients from 2018/1/1 to 2020/3/11.
- Laboratory tests are organized on the y-axis according to their impact from high to low. Individual values
- of each test for each patient are colored according to their relative values. Higher and lower values are
- shown in red and blue, respectively. Absolute SHAP values of each test are shown on the x-axis. Positive
- 289 SHAP value to the right indicates prediction of SARS-CoV-2 whereas negative SHAP value to the left
- 290 indicates prediction of influenza.
- 291 Figure 3: Impact of each laboratory test and demographic feature to the overall differentiation in the
- new SARS-CoV-2 dataset from 2020/12/1 to 2021/2/28 and the previous influenza dataset from
- 293 2018/1/1 to 2020/3/11.

295 References

- 296 1. World Health Organization (WHO). Coronavirus disease (COVID-19): Similarities and differences
- with influenza. URL: https://www.who.int/news-room/g-a-detail/coronavirus-disease-covid-19-
- 298 <u>similarities-and-differences-with-influenza</u>, 2020.
- 299 2. Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza
- 300 pandemics. *Lancet Infect Dis.* 2020;20:e238-e244.
- **301 3.** Manzanares-Meza LD, Medina-Contreras O. SARS-CoV-2 and influenza: a comparative overview
- and treatment implications. *Bol Med Hosp Infant Mex.* 2020;77:262-273.
- 303 4. Centers for Disease Control and Prevention (CDC). Overview of testing for SARS-CoV-2 (COVID-
- 304 19); URL: <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-</u>
- 305 <u>overview.html#TestingInfection</u>. Accessed June 8, 2021.
- 306 5. American Society of Microbiology. Shortages of COVID-19 and other testing supplies identified
- 307 by ASM's data collection tool. URL: <u>https://asm.org/Press-Releases/2020/October/Shortages-of-</u>
- 308 <u>COVID-19-and-Other-Testing-Supplies-I</u>. Accessed on May 26, 2021.
- 309 6. Yang HS, Hou Y, Zhang H et al. Machine learning highlights down-trending of COVID-19 patients
- 310 with a distinct laboratory profile. *Health Data Science*. 2021; Article ID 7574903. Doi:
- 311 10.34133/7574903.
- 312 7. Bayat V, Phelps S, Ryono R, et al. A SARS-CoV-2 Prediction Model from Standard Laboratory
- 313 Tests. *Clin Infect Dis.* 2020; ciaa1175. doi: 10.1093/cid/ciaa1175.
- **8.** Joshi RP, Pejaver V, Hammarlund NE, et al. A predictive tool for identification of SARS-CoV-2
- 315 PCR-negative emergency department patients using routine test results. J Clin Virol.
- 316 2020;129:104502.
- 317 9. Yang HS, Hou Y, Vasovic LV, et al. Routine Laboratory Blood Tests Predict SARS-CoV-2 Infection
- 318 Using Machine Learning. *Clin Chem.* 2020;66:1396-1404.

319	10.	Song X, Delanev	M, Shah RK,	Campos JM,	Wessel DL, DeBiasi RL	. Comparison o	f Clinical Features
					······································		

- of COVID-19 vs Seasonal Influenza A and B in US Children. JAMA Netw Open. 2020;3:e2020495.
- **11.** Singh D, Yi SV. On the origin and evolution of SARS-CoV-2. *Exp Mol Med.* 2021;53:537-547.
- 322 **12.** Olsen SJ, Azziz-Baumgartner E, Budd AP, et al. Decreased Influenza Activity During the COVID-19
- Pandemic United States, Australia, Chile, and South Africa, 2020. MMWR Morb Mortal Wkly
- *Rep.* 2020;69:1305-1309.
- **13.** Jones N. How COVID-19 is changing the cold and flu season. *Nature News Feature* 2020. URL:
- 326 <u>https://www.nature.com/articles/d41586-020-03519-3</u>. Accessed June 8, 2020.
- 327 14. Di Filippo L, Doga M, Frara S, Giustina A. Hypocalcemia in COVID-19: Prevalence, clinical
- 328 significance and therapeutic implications. *Rev Endocr Metab Disord*. 2021; doi: 10.1007/s11154329 021-09655-z.
- Di Filippo L, Formenti AM, Rovere-Querini P, et al. Hypocalcemia is highly prevalent and predicts
 hospitalization in patients with COVID-19. Endocrine. 2020;68:475-478.
- **16.** Zhou X, Chen D, Wang L, et al. Low serum calcium: a new, important indicator of COVID-19
- patients from mild/moderate to severe/critical. Biosci Rep. 2020; 40(12): BSR20202690.
- 17. Lewis C DJ. Why New York's last COVID surge was far less deadly than its first. Gothamist. URL:
- 335 <u>https://gothamist.com/news/why-new-yorks-last-covid-surge-was-far-less-deadly-than-its-first.</u>
- 336
 Last accessed: June 28, 2021. 2021.